ArticleCureus2025
Insights Into the Seroprevalence, Clinical Spectrum, and Laboratory Features of Dengue and Chikungunya Mono-Infections vs. Co-infections During 2022-2023.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Burden of Chikungunya in India: An Overview of Clinical, Epidemiological, and Public Health Challenges.Cureus · 2026Review
- Chikungunya in 2025: Comprehensive Insights into Virology, Diagnostics, Vaccines, and Antiviral Therapies.Viruses · 2026Review
- Highly Sensitive Si-Based Electrolyte-Gated Transistor Array for Multiplexed Detection of Arboviruses.Micromachines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Central India is hyperendemic for dengue and chikungunya virus infections, with yearly outbreaks being recorded. As these infections are clinically overlapping, co-infection of these viruses poses a diagnostic challenge. Therefore, it is imperative to identify them using serological or molecular tests. In this study, seroprevalence of dengue and chikungunya mono-infection as well as co-infections was estimated in suspected patients presented at our tertiary care center. Also, we compared the biochemical and other lab parameters of all the dengue and chikungunya mono-infected and co-infected IPD (Inpatient Department) patients. Methods A total of 3350 dengue and chikungunya suspected samples were recruited in this study. Sero-diagnosis of dengue was done using IgM MAC and NS-1 antigen enzyme-linked immunosorbent assay (ELISA), and chikungunya by IgM MAC ELISA. Further, we compared the demographic characteristics, temporal variations, clinical features, and biochemical parameters in patients with dengue and chikungunya mono-infection vs. co-infection. Results Seropositivity for dengue (DENV) and chikungunya (CHIKV) mono-infections was observed to be 23.86% (n=800) and 13.30% (n=444), respectively, while seropositivity for dengue and chikungunya co-infections was observed to be 6.55% (n=220). Leucopenia was significantly higher among the co-infected patients as compared to DENV and CHIKV mono-infected cases. Hypokalemia was significantly higher among the DENV patients and co-infected patients as compared to the CHIKV patients. Urea and creatinine levels were significantly elevated among the CHIKV patients as compared to DENV and co-infected patients. Conclusions Leucopenia and hypokalemia were found to be significantly high among the co-infected patients. Clinically suspected samples should be tested for both viruses, especially in the monsoon and post-monsoon seasons, as high sero-prevalence has been observed. Simultaneous diagnosis of these infections is required to diagnose dual infections and thus triage patients for monitoring and initiating supportive treatment to prevent fatal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.